COMPASS试验的外部适用性:REACH注册研究分析
本研究将COMPASS试验的入选和排除标准应用于REACH注册中冠状动脉疾病或外周动脉疾病患者,评估COMPASS合格人群比例及特征。结果显示52.9%可评估患者符合COMPASS标准,合格患者年化主要终点事件率高于COMPASS阿司匹林组(4.2% vs 2.9%/年,P<0.001)。
要点
- REACH注册中52.9%的CAD/PAD患者符合COMPASS标准,提示外部适用性良好。
- COMPASS合格患者年化主要终点事件率4.2%,高于COMPASS阿司匹林组的2.9%。
- 主要排除原因为高出血风险(51.8%)和抗凝药物使用(44.8%)。
核心结论
- COMPASS合格患者占REACH注册中稳定CAD/PAD患者的相当比例,提示COMPASS结果在常规实践中外部适用性良好。
- COMPASS合格患者的年化主要终点事件率高于COMPASS试验阿司匹林单药治疗组。
研究设计与样本
- 将COMPASS试验的入选和排除标准应用于REACH国际注册中冠状动脉疾病或外周动脉疾病患者。
- 主要复合终点为心血管死亡、心肌梗死或卒中。
主要发现
- 主要排除原因包括高出血风险(51.8%)、抗凝药物使用(44.8%)、ACS或PCI术后1年内需双联抗血小板治疗(25.9%)、1年内缺血性卒中史(12.4%)和严重肾衰竭(2.2%)。
- 单纯PAD患者合格率最高(68.4%)。
- COMPASS合格患者年化主要终点事件率为4.2%,COMPASS试验阿司匹林组为2.9%/年(P<0.001)。
临床怎么用
- 在稳定CAD/PAD患者中,约半数符合COMPASS标准,可考虑应用COMPASS试验结果指导临床决策。
- COMPASS合格患者事件风险较高,需关注出血风险及抗凝药物使用等排除因素。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
AIMS: The aims of the present study were to describe the proportion of patients eligible for the COMPASS trial within the Reduction of Atherothrombosis for Continued Health (REACH) registry, the reasons for ineligibility, and to put in perspective the characteristics and outcomes of trial-eligible patients from the REACH registry compared with those of patients enrolled in the reference aspirin arm of the COMPASS trial. METHODS AND RESULTS: The COMPASS selection and exclusion criteria were applied to REACH patients with either coronary artery disease (CAD) or peripheral artery disease (PAD). We used the COMPASS primary composite outcome of cardiovascular (CV) death, myocardial infarction (MI), or stroke. In REACH, 31 873 patients had CAD or PAD and detailed information allowing evaluation of eligibility. Among these, 9518 (29.9%) patients had exclusion criteria and an additional 5480 patients (17.2%) did not fulfil the inclusion criteria and thus were not eligible. The 'COMPASS-Eligible' population therefore comprised 52.9% of the evaluable REACH patients (n = 16 875). The main reasons for exclusion were high-bleeding risk (51.8%), anticoagulant use (44.8%), requirement for dual antiplatelet therapy within 1 year of an ACS or PCI with stent, (25.9%), history of ischaemic stroke <1 year (12.4%), and severe renal failure (2.2%). Eligibility was highest among patients with PAD alone (68.4%). COMPASS-Eligible patients from REACH experienced higher annualized primary outcome event rates than patients actually enrolled in the reference aspirin arm of COMPASS (4.2% vs. 2.9% per year, P < 0.001). CONCLUSION: COMPASS-Eligible patients represent a substantial fraction of stable CAD/PAD patients encountered in routine clinical practice in the large international REACH registry suggesting good external applicability. COMPASS-Eligible patients experienced a higher rate of the primary outcome compared with COMPASS participants in the aspirin alone treatment arm.
引用
- Darmon A, Bhatt DL, Elbez Y, et al. External applicability of the COMPASS trial: an analysis of the reduction of atherothrombosis for continued health (REACH) registry. Eur Heart J. 2018. PMID: 29186454. doi:10.1093/eurheartj/ehx658
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。